Kuwait City : On Tuesday, Pfizer and BioNTech announced that they have entered into an agreement with the Ministry of Health in Kuwait to supply the potential RNA-based vaccine BNT162 to prevent Covid-19. As per reports, the vaccine will be delivered by the end of 2020 and through 2021 after completing clinical tests and obtaining the necessary approvals from local regulatory authorities. Lindsay Ditch, Head of Pfizer's Gulf Business said that "We are extremely honored to cooperate with the Kuwaiti government to mobilize all our scientific and manufacturing resources in order to achieve our common goal of providing the potential Covid-19 vaccine to the Kuwaiti people as quickly as possible. Achieving Pfizer's goal of advancing patients lives -is more imperative than ever. We hope that our vaccine will help achieve this, but of course , it depends on success in both clinical and regulatory aspects,"
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Velit omnis animi et iure laudantium vitae, praesentium optio, sapiente distinctio illo?